448 related articles for article (PubMed ID: 12529654)
21. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
22. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia.
Niini T; Kanerva J; Vettenranta K; Saarinen-Pihkala UM; Knuutila S
Haematologica; 2000 Apr; 85(4):362-6. PubMed ID: 10756360
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia.
Nguyen TT; Ma LN; Slovak ML; Bangs CD; Cherry AM; Arber DA
Genes Chromosomes Cancer; 2006 Oct; 45(10):918-32. PubMed ID: 16858696
[TBL] [Abstract][Full Text] [Related]
24. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
[TBL] [Abstract][Full Text] [Related]
25. Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes.
Leroy H; Roumier C; Grardel-Duflos N; Macintyre E; Lepelley P; Fenaux P; Preudhomme C
Blood; 2002 May; 99(10):3848-50. PubMed ID: 11986246
[TBL] [Abstract][Full Text] [Related]
26. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
Lenny N; Meyers S; Hiebert SW
Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
[TBL] [Abstract][Full Text] [Related]
27. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
28. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
29. Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions.
Gamerdinger U; Teigler-Schlegel A; Pils S; Bruch J; Viehmann S; Keller M; Jauch A; Harbott J
Genes Chromosomes Cancer; 2003 Mar; 36(3):261-72. PubMed ID: 12557226
[TBL] [Abstract][Full Text] [Related]
30. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.
Shurtleff SA; Buijs A; Behm FG; Rubnitz JE; Raimondi SC; Hancock ML; Chan GC; Pui CH; Grosveld G; Downing JR
Leukemia; 1995 Dec; 9(12):1985-9. PubMed ID: 8609706
[TBL] [Abstract][Full Text] [Related]
31. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
32. High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan.
Liang DC; Chou TB; Chen JS; Shurtleff SA; Rubnitz JE; Downing JR; Pui CH; Shih LY
Leukemia; 1996 Jun; 10(6):991-3. PubMed ID: 8667657
[TBL] [Abstract][Full Text] [Related]
33. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
34. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
35. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
Jiao B; Wu CF; Liang Y; Chen HM; Xiong SM; Chen B; Shi JY; Wang YY; Wang JH; Chen Y; Li JM; Gu LJ; Tang JY; Shen ZX; Gu BW; Zhao WL; Chen Z; Chen SJ
Leukemia; 2009 Sep; 23(9):1598-604. PubMed ID: 19458628
[TBL] [Abstract][Full Text] [Related]
36. AML1-ETO positive AML: first report from India.
Dutta P; Hasan SK; Sazawal S; Kumar B; Bhattacharyya J; Jain M; Tyagi S; Kumar R; Pati HP; Saxena R
Indian J Pathol Microbiol; 2007 Jul; 50(3):652-4. PubMed ID: 17883173
[TBL] [Abstract][Full Text] [Related]
37. [The role of TEL and AML1 genes in the pathogenesis of hematologic malignancies].
Zuna J
Cas Lek Cesk; 2001 Mar; 140(5):131-7. PubMed ID: 11347199
[TBL] [Abstract][Full Text] [Related]
38. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
[TBL] [Abstract][Full Text] [Related]
39. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
[TBL] [Abstract][Full Text] [Related]
40. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]